Lyell Immunopharma (NASDAQ:LYEL) Upgraded at Wall Street Zen
by Amy Steele · The Cerbat GemWall Street Zen upgraded shares of Lyell Immunopharma (NASDAQ:LYEL – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.
Several other research analysts also recently issued reports on the stock. Zacks Research downgraded shares of Lyell Immunopharma from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 7th. Needham & Company LLC started coverage on shares of Lyell Immunopharma in a research report on Friday, April 10th. They set a “buy” rating and a $44.00 price target for the company. Citizens Jmp assumed coverage on shares of Lyell Immunopharma in a report on Monday, March 9th. They issued a “market outperform” rating and a $34.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $41.00.
View Our Latest Analysis on Lyell Immunopharma
Lyell Immunopharma Price Performance
LYEL opened at $24.89 on Friday. The firm has a market cap of $580.68 million, a PE ratio of -1.53 and a beta of -0.06. The stock has a 50-day moving average price of $22.65 and a 200-day moving average price of $23.18. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00.
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($7.68) EPS for the quarter, missing the consensus estimate of ($2.15) by ($5.53). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.02 million. Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. As a group, sell-side analysts anticipate that Lyell Immunopharma will post -10.45 EPS for the current year.
Insider Buying and Selling at Lyell Immunopharma
In other Lyell Immunopharma news, insider Gary K. Lee sold 1,671 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $39,084.69. Following the transaction, the insider owned 16,938 shares in the company, valued at approximately $396,179.82. This represents a 8.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Stephen J. Hill sold 1,236 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $28,910.04. Following the sale, the chief operating officer directly owned 17,795 shares in the company, valued at approximately $416,225.05. The trade was a 6.49% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 11,310 shares of company stock worth $264,285. Company insiders own 22.30% of the company’s stock.
Institutional Investors Weigh In On Lyell Immunopharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in LYEL. Invesco Ltd. bought a new stake in Lyell Immunopharma in the 4th quarter worth approximately $3,036,000. MWG Caph Ltd bought a new position in shares of Lyell Immunopharma during the 4th quarter valued at $31,030,000. ExodusPoint Capital Management LP purchased a new position in shares of Lyell Immunopharma in the 4th quarter worth $262,000. Barclays PLC grew its holdings in shares of Lyell Immunopharma by 1,239.5% in the fourth quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma in the fourth quarter worth $2,257,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.